RE:RE:RE:Trial with unique way to deliver DocetaxelIf THTX's therapeutic window is larger as seems likely, can you explain what that means for the success of TH-1902 from a commercial perspective? I think we can guess but I would rather get a clearer read on that from someone with your background.
Is there anything in the PK or PD info in that article that has any relevance for TH-1902? Hopefully, JFM1330 will weigh in on that as he clearly understands those aspects of it better than most of us.
Micelles are like small spheres that have structures similar to cell membranes that allow them to fuse with the membrane and deposit their content (docetaxel) into the cell. So better delivery of chemo to cell but the problem is it does this to all cells. Just looking at the abstract the results fit that. They can dose lower to get efficacy but seems like some DLTs also appear. It doesn't look like they've increased the therapeutic window size just shifted everything (efficacy and toxicity) to a lower dose. It might be more subtle than that and the toxicity profile might be better, I can't judge, but my first guess is the therapeutic window just moved, it didn't get bigger.
SPCEO1 wrote: My guess is there could be some interesting aspects to this paper for us and am looking forward to any comments JFM1330 and Qwerty might have about it. I could make some uneducated comments but that would likely be wasting everybody's time.
jeffm34 wrote: https://www.sciencedirect.com/science/article/pii/S0168365920303540
This was a phase I dose escalation trial as well. I assume Thera will be monitoring tumour size in each patient after every treatment cycle as well. Which means they should be seeing efficacy data all the way along the trial.
"The total tumour burden measured in this patient decreased from 129 mm at screening to 109 mm in cycle 2, 90 mm in cycle 4, 86 mm in cycle 6 and 85 mm at EOT."
[/quote]